全文获取类型
收费全文 | 14352篇 |
免费 | 821篇 |
国内免费 | 125篇 |
专业分类
耳鼻咽喉 | 83篇 |
儿科学 | 289篇 |
妇产科学 | 304篇 |
基础医学 | 1933篇 |
口腔科学 | 275篇 |
临床医学 | 916篇 |
内科学 | 3546篇 |
皮肤病学 | 474篇 |
神经病学 | 1042篇 |
特种医学 | 561篇 |
外科学 | 2298篇 |
综合类 | 35篇 |
预防医学 | 402篇 |
眼科学 | 195篇 |
药学 | 1042篇 |
中国医学 | 41篇 |
肿瘤学 | 1862篇 |
出版年
2023年 | 68篇 |
2022年 | 56篇 |
2021年 | 288篇 |
2020年 | 175篇 |
2019年 | 219篇 |
2018年 | 292篇 |
2017年 | 299篇 |
2016年 | 326篇 |
2015年 | 356篇 |
2014年 | 432篇 |
2013年 | 529篇 |
2012年 | 874篇 |
2011年 | 917篇 |
2010年 | 516篇 |
2009年 | 409篇 |
2008年 | 741篇 |
2007年 | 808篇 |
2006年 | 792篇 |
2005年 | 792篇 |
2004年 | 736篇 |
2003年 | 781篇 |
2002年 | 736篇 |
2001年 | 336篇 |
2000年 | 318篇 |
1999年 | 288篇 |
1998年 | 198篇 |
1997年 | 147篇 |
1996年 | 123篇 |
1995年 | 127篇 |
1994年 | 99篇 |
1993年 | 95篇 |
1992年 | 216篇 |
1991年 | 191篇 |
1990年 | 186篇 |
1989年 | 231篇 |
1988年 | 207篇 |
1987年 | 184篇 |
1986年 | 160篇 |
1985年 | 152篇 |
1984年 | 98篇 |
1983年 | 76篇 |
1982年 | 60篇 |
1981年 | 50篇 |
1979年 | 87篇 |
1978年 | 66篇 |
1977年 | 45篇 |
1976年 | 44篇 |
1974年 | 50篇 |
1973年 | 42篇 |
1972年 | 40篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Harada Hideyuki Omori Shota Mori Keita Konno Masahiro Murakami Haruyasu Imagumbai Toshiyuki Fukuda Haruyuki Nakamatsu Kiyoshi Kimura Tomoki Tanabe Hiroaki Fujita Hideki Tatebe Hitoshi Fujitaka Kazunori Nishimura Yasumasa 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(6):1025-1033
International Journal of Clinical Oncology - This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced... 相似文献
2.
Takafumi Koyama Toshio Shimizu Satoru Iwasa Yutaka Fujiwara Shunsuke Kondo Shigehisa Kitano Kan Yonemori Akihiko Shimomura Sakura Iizumi Tatsuya Sasaki Junji Furuse Noboru Yamamoto 《Cancer science》2020,111(2):571-579
Fibroblast growth factor receptors (FGFR) are a family of transmembrane receptor tyrosine kinases involved in regulating cellular processes. FGFR mutations are implicated in oncogenesis, representing therapeutic potential in the form of FGFR inhibitors. This phase I, first‐in‐human study in Japan evaluated safety and tolerability of E7090, a potent selective FGFR1‐3 inhibitor, in patients with advanced solid tumors. Dose escalation (daily oral dose of 1‐180 mg) was carried out to assess dose‐limiting toxicity (DLT), maximum tolerated dose, and pharmacokinetics. Pharmacodynamic markers (serum phosphate, fibroblast growth factor 23, and 1,25‐(OH)2‐vitamin D) were also evaluated. A total of 24 patients refractory to standard therapy or for whom no appropriate treatment was available were enrolled. No DLT were observed up to the 140‐mg dose; one patient in the 180‐mg cohort experienced a DLT (increased aspartate aminotransferase/alanine aminotransferase, grade 3). The maximum tolerated dose was not reached. Dose‐dependent increases in the maximum concentration and area under the curve from time 0 to the last measurable concentration were observed up to 180 mg. Dose‐dependent increases were observed in all pharmacodynamic markers and plateaued at 100‐140 mg, indicating sufficient FGFR pathway inhibition at doses ≥100 mg. In conclusion, E7090 showed a manageable safety profile with no DLT at doses ≤140 mg. Maximum tolerated dose was not determined. The recommended dose for the follow‐up expansion part, restricted to patients with tumors harboring FGFR alterations, was determined as 140 mg, once daily. 相似文献
3.
Shinichi Tsuruta Kenichi Kohashi Yuichi Yamada Minako Fujiwara Yutaka Koga Eikichi Ihara Yoshihiro Ogawa Eiji Oki Masafumi Nakamura Yoshinao Oda 《Cancer science》2020,111(3):1008-1019
ARID1A, one of the subunits in SWI/SNF chromatin remodeling complex, is frequently mutated in gastric cancers with microsatellite instability (MSI). The most frequent MSI in solid‐type poorly differentiated adenocarcinoma (PDA) has been reported, but the SWI/SNF complex status in solid‐type PDA is still largely unknown. We retrospectively analyzed 54 cases of solid‐type PDA for the expressions of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6), SWI/SNF complex subunits (ARID1A, INI1, BRG1, BRM, BAF155, and BAF170) and EBER, and mutations in KRAS and BRAF. We analyzed 40 cases of another histological type of gastric cancer as a control group. The solid‐type PDAs showed coexisting glandular components (76%), MMR deficiency (39%), and complete/partial loss of ARID1A (31%/7%), INI1 (4%/4%), BRG1 (48%/30%), BRM (33%/33%), BAF155 (13%/41%), and BAF170 (6%/2%), EBER positivity (4%), KRAS mutation (2%), and BRAF mutation (2%). Compared to the control group, MMR deficiency and losses of ARID1A, BRG1, BRM, and BAF155 were significantly frequent in solid‐type PDAs. Mismatch repair deficiency was associated with the losses of ARID1A, BRG1, and BAF155 in solid‐type PDAs. In the MMR‐deficient group, solid components showed significantly more frequent losses of ARID1A, BRG1, BRM, and BAF155 compared to glandular components (P = .0268, P = .0181, P = .0224, and P = .0071, respectively). In the MMR‐proficient group, solid components showed significantly more frequent loss of BRG1 compared to glandular components (P = .012). In conclusion, solid‐type PDAs showed frequent losses of MMR proteins and the SWI/SNF complex. We suggest that loss of the SWI/SNF complex could induce a morphological shift from differentiated‐type adenocarcinoma to solid‐type PDA. 相似文献
4.
5.
6.
Yasushi Sawayama Hidehiro Itonaga Takuya Fukushima Nobuaki Nakano Hiroshi Fujiwara Atae Utsunomiya Takahiro Fukuda Toshihiro Miyamoto Tetsuya Eto Kaname Miyashita Hirohisa Nakamae Masao Ogata Atsushi Yamanoha Yasuhiko Miyazaki Junya Kanda Yoshiko Atsuta Koji Kato ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation 《American journal of hematology》2019,94(5):E143-E146
7.
8.
9.
Taichi Imaizumi Keiko Yamamoto-Shimojima Hitoshi Yamamoto Toshiyuki Yamamoto 《Congenital anomalies》2020,60(1):10-14
Genomic copy number variations (CNVs) can be detected by chromosomal microarray testing. However, upon final diagnosis, other methods may be recommended for a validation method to confirm CNVs. Trio analyses or carrier detection in family members are also frequently required. Previously, fluorescence in situ hybridization and/or quantitative PCR have been used; however, these methods present limitations. The purpose of this study was to establish a simple and rapid method to detect genomic copy numbers. We utilized droplet digital PCR (dPCR) with an intercalation method. Thirteen patients, who were diagnosed with MECP2 duplications via chromosomal microarray testing, were enrolled in this study. Four of their female relatives, who were verified as carriers of MECP2 duplications, were also included. Genomic copy numbers of MECP2 and IRAK1 were analyzed in comparison with reference genes: XIST and AR on the X-chromosome, and RPP30 and RPPH1 on the autosomal chromosomes. As a result, genomic copy numbers of MECP2 were rapidly and precisely detected by the dPCR system established in this study. This method can be widely applied as a diagnostic method to confirm CNVs on other chromosomal regions. 相似文献
10.